| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
DAUDA does not have a specific biological target but functions as a fluorescent probe for fatty acid binding proteins. As an environment-sensitive fluorescent fatty acid analogue, DAUDA changes its fluorescence properties upon binding to proteins. It is used to study the binding affinity of fatty acids to fatty acid binding proteins (e.g., Sm14 from Schistosoma mansoni). Its fluorescence properties make it a valuable tool for studying lipid-protein interactions and fatty acid binding.
|
|---|---|
| ln Vitro |
In vitro, DAUDA is used as a fluorescent probe to study fatty acid binding proteins. Its fluorescence intensity and emission spectrum change upon binding to proteins. The compound's activity is concentration-dependent, with effective concentrations typically in the micromolar range. In binding assays, DAUDA is used to determine the relative affinity of natural fatty acids for fatty acid binding proteins. Its environment-sensitive fluorescence makes it a valuable tool for studying lipid-protein interactions and fatty acid binding.
|
| ln Vivo |
In vivo, DAUDA is not used as a therapeutic agent. It is a fluorescent probe used in biochemical and biophysical research. Its in vivo applications are limited to research settings, where it may be used to study fatty acid binding proteins in tissue samples. The compound is not administered to animals for therapeutic purposes. Its in vivo applications are limited to ex vivo studies. The compound is for research use only and is not approved for human therapeutic applications.
|
| Enzyme Assay |
The in vitro fatty acid binding assay for DAUDA typically uses purified fatty acid binding proteins (e.g., Sm14 from S. mansoni). The assay is performed in 96-well plates with the protein, varying concentrations of DAUDA (typically 0.1 to 100 µM), and competing natural fatty acids. Fluorescence is measured at excitation/emission wavelengths appropriate for DAUDA. The displacement of DAUDA by natural fatty acids is used to determine the relative affinity of the fatty acids for the binding protein. Binding constants are calculated from competition curves. Positive controls (e.g., known fatty acid binders) and negative controls (buffer only) are included in each assay run.
|
| Cell Assay |
For in vitro cellular assays, cells or tissue homogenates containing fatty acid binding proteins are incubated with DAUDA at concentrations ranging from 0.1 to 100 µM. Fluorescence is measured using a fluorescence plate reader or spectrofluorometer. The binding of DAUDA to proteins is assessed by changes in fluorescence intensity or emission spectra. Cell viability is assessed using MTT or CellTiter-Glo assays. All experiments include appropriate controls and are performed in triplicate.
|
| Animal Protocol |
For in vivo studies, DAUDA is not typically administered to animals as a therapeutic agent. It may be used in ex vivo studies on tissue samples. Tissues are harvested and homogenized, and DAUDA is added to the homogenates for fatty acid binding assays. All animal procedures should be conducted in accordance with institutional guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of DAUDA are not relevant, as it is a fluorescent probe rather than a therapeutic agent. The compound has a molecular weight of 434.59. It is a lipophilic molecule. It is used in vitro and ex vivo for fluorescence-based assays. The compound should be stored protected from light to prevent photobleaching. Detailed PK data are not available in publicly accessible literature.
|
| Toxicity/Toxicokinetics |
The toxicology of DAUDA is primarily related to its use as a fluorescent probe. At the low concentrations used for fluorescence assays (typically 0.1 to 100 µM), it is generally considered non-toxic to cells. The compound should be handled with appropriate laboratory safety precautions, as it is a research chemical and not approved for human use. Comprehensive toxicology studies would be required if the compound were to be used for therapeutic applications.
|
| References | |
| Additional Infomation |
DAUDA is a sulfonic acid derivative, belonging to the naphthalene class of compounds.
DAUDA (11-(Dansylamino)undecanoic acid) is an environment-sensitive fluorescent fatty acid analogue. It alters its fluorescence on entry into binding proteins. It is used to determine the relative affinity of natural fatty acids for fatty acid binding proteins. It is not approved for human use and is intended for research purposes only. It is available as a high-purity research reagent for laboratory use. |
| Molecular Formula |
C23H34N2O4S
|
|---|---|
| Molecular Weight |
434.59206
|
| Exact Mass |
434.223
|
| CAS # |
73025-02-2
|
| PubChem CID |
122016
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
607.9±53.0 °C at 760 mmHg
|
| Flash Point |
321.5±30.9 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.573
|
| LogP |
5.87
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
30
|
| Complexity |
603
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
CEPGVMDMVJGHFQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H34N2O4S/c1-25(2)21-15-11-14-20-19(21)13-12-16-22(20)30(28,29)24-18-10-8-6-4-3-5-7-9-17-23(26)27/h11-16,24H,3-10,17-18H2,1-2H3,(H,26,27)
|
| Chemical Name |
11-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]undecanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~230.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3010 mL | 11.5051 mL | 23.0102 mL | |
| 5 mM | 0.4602 mL | 2.3010 mL | 4.6020 mL | |
| 10 mM | 0.2301 mL | 1.1505 mL | 2.3010 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
